IQVIA Holdings Inc. $IQV Position Cut by Exencial Wealth Advisors LLC

Exencial Wealth Advisors LLC trimmed its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 5.0% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 40,511 shares of the medical research company’s stock after selling 2,147 shares during the quarter. Exencial Wealth Advisors LLC’s holdings in IQVIA were worth $6,384,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Mather Group LLC. grew its holdings in IQVIA by 83.5% in the 1st quarter. Mather Group LLC. now owns 769 shares of the medical research company’s stock worth $136,000 after buying an additional 350 shares in the last quarter. Patton Fund Management Inc. acquired a new stake in IQVIA in the second quarter worth approximately $231,000. Verdence Capital Advisors LLC acquired a new stake in IQVIA in the second quarter worth approximately $3,612,000. Private Advisor Group LLC lifted its position in IQVIA by 11.6% in the first quarter. Private Advisor Group LLC now owns 5,435 shares of the medical research company’s stock worth $958,000 after purchasing an additional 566 shares during the period. Finally, Raleigh Capital Management Inc. lifted its position in IQVIA by 85.5% in the second quarter. Raleigh Capital Management Inc. now owns 3,350 shares of the medical research company’s stock worth $528,000 after purchasing an additional 1,544 shares during the period. 89.62% of the stock is owned by institutional investors.

IQVIA Price Performance

IQV opened at $218.96 on Wednesday. The stock has a fifty day moving average of $192.71 and a 200-day moving average of $169.95. The firm has a market capitalization of $37.22 billion, a P/E ratio of 31.69, a PEG ratio of 2.33 and a beta of 1.32. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $231.34. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.04. The company had revenue of $4.02 billion during the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The company’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.64 earnings per share. Equities analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

IQV has been the subject of a number of research analyst reports. Redburn Partners set a $214.00 target price on IQVIA in a research report on Wednesday, September 3rd. Truist Financial upped their target price on IQVIA from $209.00 to $235.00 and gave the stock a “buy” rating in a research report on Wednesday, July 23rd. Jefferies Financial Group upgraded IQVIA from a “hold” rating to a “buy” rating and upped their target price for the stock from $195.00 to $225.00 in a research report on Tuesday, September 9th. Robert W. Baird upped their target price on IQVIA from $159.00 to $196.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 23rd. Finally, Cowen restated a “buy” rating on shares of IQVIA in a research report on Wednesday, July 23rd. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and an average target price of $234.57.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.